Manufacturer
L.B.S. LABS LTD PART
Contents
Triamcinolone acetonide
Indication
Inflammatory joint diseases, Inflammatory skin conditions, Symptomatic control for hay fever, Suppression of allergic and inflammatory disorders, Inflammatory eye disorders, Visualisation during vitrectomy, Bursitis, Tendinitis.
Instruction
Administer via Intradermal/ Intra-Articular/ IM injection/Intravitreal/Periarticular.
Drug interaction
May antagonise effect of anticholinesterase agent. Additional increase of intraocular pressure with anticholinergics (e.g. atropine). May potentiate or reduce anticoagulant effect of oral anticoagulants. May increase hyperglycaemic effect of ceritinib. May diminish the therapeutic effect of antidiabetics (e.g. sulfonylurea derivatives) and insulin. May diminish arterial blood pressure reduction of antihypertensives (including diuretics). May reduce isoniazid serum concentrations. Increase in both ciclosporin and corticosteroids activity when used concomitantly. May increase toxicity of digitalis glycosides. Increased effects with ketoconazole. May alter the neuromuscular blocking action of non-depolarising muscle relaxants. May increase risk of gastrointestinal bleeding and ulceration associated with NSAIDs. Increased serum levels with oestrogen (including oral contraceptives). Neurological complications and diminished antibody response may occur on vaccinated patients. May develop hypokalaemia with K-depleting agents (e.g. amphotericin B inj, diuretics). May increase risk of QT prolongation or torsade de pointes with class Ia antiarrhythmics (e.g. disopyramide, quinidine, procainamide) or class II antiarrhythmics (e.g. amiodarone, sotalol, bepridil).
Malaysia
